Brunton, LL (ed.) (2018) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th edition. New York, NY: McGraw Medical.Google Scholar

Schatzberg, AF, Nemeroff, CB (eds.) (2017) Textbook of Psychopharmacology, 5th edition. Washington, DC: American Psychiatric Publishing.Google Scholar

Cummings, M, Stahl, SM (2021) Management of Complex, Treatment-Resistant Psychiatric Disorders. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Goldberg, J, Stahl, SM (2021) Practical Psychopharmacology. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Kalali, A, Kwentus, J, Preskorn, S, Stahl, SM (eds.) (2012) Essential CNS Drug Development. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Marazzitti, D, Stahl, SM (2019) Evil, Terrorism and Psychiatry. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Moutier, C, Pisani, A, Stahl, SM (2021) Stahl’s Handbooks: Suicide Prevention Handbook. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Pappagallo, M, Smith, H, Stahl, SM (2012) Essential Pain Pharmacology: the Prescribers Guide. Cambridge: Cambridge University Press.Google Scholar

de Oliveira I, Reis, Schwartz, T, Stahl, SM. (2014) Integrating Psychotherapy and Psychopharmacology. New York, NY: Routledge Press.Google Scholar

Silberstein, SD, Marmura, MJ, Hsiangkuo, Y, Stahl, SM (2016) Essential Neuropharmacology: the Prescribers Guide, 2nd edition. Cambridge: Cambridge University Press.Google Scholar

Stahl, SM (2009) Stahl’s Illustrated: Antidepressants. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM (2009) Stahl’s Ilustrated: Mood Stabilizers. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM (2009) Stahl’s Illustrated: Chronic Pain and Fibromyalgia. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Mignon, L (2009) Stahl’s Illustrated: Attention Deficit Hyperactivity Disorder. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Mignon, L (2010) Stahl’s Illustrated: Antipsychotics, 2nd edition. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Grady, MM (2010) Stahl’s Illustrated: Anxiety and PTSD. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM (2011) Essential Psychopharmacology Case Studies. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM (2018) Stahl’s Essential Psychopharmacology: the Prescribers Guide Children and Adolescents. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM (2019) Stahl’s Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians, 3rd edition. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM (2021) Stahl’s Essential Psychopharmacology: the Prescribers Guide, 7th edition. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Davis, RL (2011) Best Practices for Medical Educators, 2nd edition. Cambridge: Cambridge University Press.Google Scholar

Stahl, SM, Grady, MM (2012) Stahl’s Illustrated: Substance Use and Impulsive Disorders. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Moore, BA (eds.) (2013) Anxiety Disorders: a Concise Guide and Casebook for Psychopharmacology and Psychotherapy Integration. New York, NY: Routledge Press.CrossRefGoogle Scholar

Stahl, SM, Morrissette, DA (2014) Stahl’s Illustrated: Violence: Neural Circuits, Genetics and Treatment. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Morrissette, DA (2016) Stahl’s Illustrated: Sleep and Wake Disorders, Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stahl, SM, Morrissette, DA (2018) Stahl’s Illustrated: Dementia. Cambridge: Cambridge University Press..Google Scholar

Stahl, SM, Schwartz, T (2016) Case Studies: Stahl’s Essential Psychopharmacology, Volume 2. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Stein, DJ, Lerer, B, Stahl, SM (eds.) (2012) Essential Evidence Based Psychopharmacolgy, 2nd edition. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Warburton, KD, Stahl, SM (2016) Violence in Psychiatry. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Warburton, KD, Stahl, SM (2021) Decriminalizing Mental Illness. Cambridge: Cambridge University Press.CrossRefGoogle Scholar

Byrne, JH, Roberts, JL (eds.) (2004) From Molecules to Networds: An Introduction to Cellular and Molecular Neuroscience. New York, NY: Elsevier.Google Scholar

Charney, DS, Buxbaum, JD, Sklar, P, Nestler, EJ (2018) Charney and Nestler’s Neurbiology of Mental Illness, 5th edition. New York, NY: Oxford University Press.Google Scholar

Iversen, LL, Iversen, SD, Bloom, FE, Roth, RH (2009) Introduction to Neuropsychopharmacology. New York, NY: Oxford University Press.CrossRefGoogle Scholar

Meyer, JS, Quenzer, LF (2019) Psychopharmacology: Drugs, the Brain, and Behavior, 3rd edition. New York, NY: Sinauer Associates, Oxford University Press.Google Scholar

Nestler, EJ, Kenny, PJ, Russo, SJ, Schaefer, A (2020) Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, 4th edition. New York, NY: McGraw Medical.Google Scholar

Purves, D, Augustine, GJ, Fitzpatrick, D, et al. (2018) Neuroscience, 6th edition. New York, NY: Sinauer Associates, Oxford University Press.Google Scholar

Squire, LR, Berg, D, Bloom, FE, et al. (eds.) (2012) Fundamental Neuroscience, 4th edition. San Diego, CA: Academic Press.Google Scholar

Alex, KD, Pehak, EA (2007) Pharmacological mechanisms of serotoninergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296–320.CrossRefGoogle Scholar

Amargos-Bosch, M, Bortolozzi, A, Buig, MV, et al. (2004) Co-expression and in vivo interaction of serotonin 1A and serotonin 2A receptors in pyramidal neurons of prefrontal cortex. Cerbral Cortex 14: 281–99.Google ScholarPubMed

Baez, MV, Cercata, MC, Jerusalinsky, DA (2018) NMDA receptor subunits change after synaptic plasticity induction and learning and memory acquisition. Neural Plast, doi.org/10,1155/2018/5093048.CrossRefGoogle Scholar

Beaulier, JM, Gainetdinov, RR (2011) The physiology, signaling and pharmacology of dopamine receptors. Pharmacol Rev 63: 182–217.CrossRefGoogle Scholar

Belmer, A, Quentin, E, Diaz, SL, et al. (2018) Positive regulation of raphe serotonin neurons by serotonin 2B receptors. Neuropsychopharmacology 42: 1623–32.Google Scholar

Calabresi, P, Picconi, B, Tozzi, A, Ghiglieri, V, Di Fillippo, M (2014) Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neurosci 17: 1022–30.CrossRefGoogle ScholarPubMed

Cathala, A, Devroye, C, Drutel, G, et al. (2019) Serotonin 2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitor control on serotonin neurons. Exp Neurol 311: 57–66.CrossRefGoogle ScholarPubMed

De Bartolomeis, A, Fiore, G, Iasevoli, F (2005) Dopamine glutamate interaction and antipsychotics mechanism of action: implication for new pharmacologic strategies in psychosis. Curr Pharmaceut Design 11: 3561–94.CrossRefGoogle ScholarPubMed

DeLong, MR, Wichmann, T (2007) Circuits and Ciruit disorders of the basal ganglia. Arch Neurol 64: 20–4.CrossRefGoogle Scholar

Fink, KB, Gothert, M (2007) 5HT receptor regulation of neurotransmitter release. Pharmacol Rev 59: 360–417.CrossRefGoogle ScholarPubMed

Hansen, KB, Yi, F, Perszyk, RE, et al (2018) Structure, function and allosteric modulation of NMDA receptors. J Gen Physiol 150: 1081–105.CrossRefGoogle ScholarPubMed

Homayoun, H, Moghaddam, B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496–500.CrossRefGoogle ScholarPubMed

Nicoll, RA (2017) A brief history of long-term potentiation. Neuron 93: 281–99.CrossRefGoogle ScholarPubMed

Paoletti, P, Neyton, J (2007) NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7: 39–47.CrossRefGoogle ScholarPubMed

Scheefhals, N, MacGillavry, HD (2018) Functional organization of postsynaptic glutamate receptors. Mol Cell Neurosci 91: 82–94.CrossRefGoogle ScholarPubMed

Sokoloff, P, Le Foil, B (2017) The dopamine D₃ receptor: a quarter century later. Eur J Neurosci 45: 2–19.CrossRefGoogle ScholarPubMed

Stahl, SM (2017) Dazzled by the dominions of dopamine: clinical roles of D₃, D₂, and D₁ receptors. CNS Spectrums 22: 305–11.CrossRefGoogle ScholarPubMed

Aghajanian, GK, Marek, GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31: 302–12.CrossRefGoogle ScholarPubMed

Bloomfield, MAP, Morgan, CJA, Egerton, A, et al. (2014) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75: 470–8.CrossRefGoogle ScholarPubMed

Brugger, SP, Anelescu, I, Abi-Dargham, A, et al. (2020) Heterogeneity and striatal dopamine function in schizophrenia: meta analysis of variance. Biol Psychiatry 67: 215–24.Google Scholar

Bubenikova-Valesova, V, Horacek, J, Vrajova, M, et al. (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32: 1014–23.CrossRefGoogle ScholarPubMed

Demjaha, A, Murray, RM, McGuire, PK (2012) Dopamine synthesis capacity in patients with treatment resistant schizophrenia. Am J Psychiatry 169: 1203–10.CrossRefGoogle ScholarPubMed

Driesen, N, McCarthy, G, Bhagwagar, Z, et al (2013) The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacol 38: 2613–22.CrossRefGoogle ScholarPubMed

Egerton, A, Chaddock, CA, Winton-Brown, TT, et al. (2013) Presynaptic striatal dopamine dysfunction in people at ultra high risk for psychosis: findings in a second cohort. Biol Psychiatry 74: 106–12.CrossRefGoogle ScholarPubMed

Gellings Lowe, N, Rapagnani, MP, Mattei, C, Stahl, SM (2012)The psychopharmacology of hallucinations: ironic insights into mechanisms of action. In The Neuroscience of Hallucinations, Jardri, R, Thomas, P, Cachia, A and Pins, D. (eds.), Berlin: Springer, 471–92.Google Scholar

Howes, OD, Bose, SK, Turkheimer, F, et al. (2011) Dopamine synthsis capacity before onset of psychosis: a prospective ¹⁸F-DOPA PET imaging study. Am J Psychiatry 169: 1311–17.Google Scholar

Howes, OD, Montgomery, AJ, Asselin, MC, et al. (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13–20.CrossRefGoogle ScholarPubMed

Juahar, S, Nour, MM, Veronese, M, et al. (2017) A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 74: 1206–13.Google Scholar

Lodge, DJ, Grace, AA (2011) Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 32: 507–13.CrossRefGoogle ScholarPubMed

McCutcheon, RA, Abi-Dargham, A, Howes, OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42: 205–20.CrossRefGoogle ScholarPubMed

Mizrahi, R, Kenk, M, Suridjan, I, et al (2014) Stress induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39: 1479–89.CrossRefGoogle ScholarPubMed

Paz, RD, Tardito, S, Atzori, M (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 18: 773–86.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Parkinson’s disease psychosis as a serotonin–dopamine imbalance syndrome. CNS Spectrums 21: 355–9.CrossRefGoogle ScholarPubMed

Stahl, SM (2018) Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectrums 23: 187–91.CrossRefGoogle ScholarPubMed

Weinstein, JJ, Chohan, MO, Slifstein, M, et al. (2017) Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry 81: 31–42.CrossRefGoogle ScholarPubMed

Alphs, LD, Summerfelt, A, Lann, H, Muller, RJ (1989) The Negative Symptom Assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 25: 159–63.Google ScholarPubMed

Arango, C, Rapado-Castro, M, Reig, S, et al. (2012) Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry 69: 16–26.CrossRefGoogle ScholarPubMed

Cruz, DA, Weawver, CL, Lovallo, EM, Melchitzky, DS, Lewis, DA. (2009) Selective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 34: 2112–24.CrossRefGoogle ScholarPubMed

Dragt, S, Nieman, DH, Schultze-Lutter, F, et al. (2012) Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand 125: 45–53.CrossRefGoogle ScholarPubMed

Eisenberg, DP, Berman, KF (2010) Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 35: 258–77.CrossRefGoogle ScholarPubMed

Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 167: 987–93.CrossRefGoogle ScholarPubMed

Fusar-Poli, P, Bonoldi, I, Yung, AR, et al. (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69: 220–9.CrossRefGoogle ScholarPubMed

Goff, DC, Zeng, B, Ardelani, BA, et al. (2018) Association of hippocampal atrophy with duration of untreated psychosis and molecular biomarkers during initial antipsychotic treatment of first episode psychosis. JAMA Psychiatry 75: 370–8.CrossRefGoogle ScholarPubMed

Henry, LP, Amminger, GP, Harris, MG, et al. (2010) The EPPIC follow up study of first episode psychosis: longer term clinical and functional outcome 7 years after index admission. J Clin Psychiatry 71: 716–28.CrossRefGoogle ScholarPubMed

Kane, JM, Robinson, DG, Schooler, NR, et al. (2016) Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 173: 362–72.CrossRefGoogle ScholarPubMed

Kendler, KS, Ohlsson, H, Sundquist, J, et al. (2019) Prediction of onset of substance induced psychotic disorder and its progression to schizophrenia in a Swedish National Sample. Am J Psychiatry 176: 711–19.CrossRefGoogle Scholar

Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O (2011) Cannabis use and earlier onset of psychosis. Arch Gen Psychiatry 68: 555–61.CrossRefGoogle ScholarPubMed

Lieberman, JA, Small, SA, Girgis, RR (2019) Early detection and preventive intervention in schizophrenia: from fantasy to reality. Am J Psychiatry 176: 794–810.CrossRefGoogle ScholarPubMed

Mechelli, A, Riecher-Rossler, A, Meisenzahl, EM, et al. (2011) Neuroanatomical abnormalities that predate the onset of psychosis. Arch Gen Psychiatry 68: 489–95.CrossRefGoogle ScholarPubMed

Morrissette, DA, Stahl, SM (2014) Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums 19: 439–48.CrossRefGoogle ScholarPubMed

Stahl, SM (2014) Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectrums 19: 357–65.CrossRefGoogle ScholarPubMed

Stahl, SM (2015) Is impulsive violence an addiction? The habit hypothesis. CNS Spectrums 20: 165–9.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA, Cummings, M (2014) California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectrums 19: 449–65.CrossRefGoogle ScholarPubMed

Wykes, T, Huddy, V, Cellard, C, McGurk, SR, Czobar, P (2011) A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 168: 472–85.CrossRefGoogle ScholarPubMed

Artukoglu, BB, Li, F, Szejko, N, et al. (2020) Pharmacologic treatment of tardive dyskinesia: a meta analysis and systematic review. J Clin Psychiatry 81: e1–11.CrossRefGoogle ScholarPubMed

Bhidayasin, R, Jitkretsandakul, O, Friedman, JH (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 389: 67–75.CrossRefGoogle Scholar

Carbon, M, Kane, JM, Leucht, S, et al. (2018) Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta analysis. World Psychiatry 173: 330–40.Google Scholar

Citrome, L (2017) Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Practice, doi.org 10.1111/ijcp.12964.CrossRefGoogle Scholar

Citrome, L (2017) Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Practice, doi.org 10.1111/ijcp.13030.CrossRefGoogle Scholar

Jacobsen, FM (2015) Second generation antipsychotics and tardive syndromes in affective illness: a public health problem with neuropsychiatric consequences. Am J Public Health 105: e10–16.CrossRefGoogle ScholarPubMed

Niemann, N, Jankovic, J (2018) Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 78: 525–41.Google ScholarPubMed

Stahl, SM (2017) Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum. CNS Spectrums 22: 427–34.CrossRefGoogle ScholarPubMed

Stahl, SM (2018) Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects. CNS Spectrums 23: 1–6.CrossRefGoogle ScholarPubMed

Stahl, SM (2018) Comparing pharmacological mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectrums 23: 239–47.CrossRefGoogle ScholarPubMed

Woods, SW, Morgenstern, H, Saksa, JR, et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71: 463–74.CrossRefGoogle ScholarPubMed

Brissos, S, Veguilla, MR, Taylor, D, et al. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 4: 198–219.CrossRefGoogle ScholarPubMed

Kishimoto, T, Nitto, M, Borenstein, M, et al. (2013) Long acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta analysis of mirror image studies. J Clin Psychiatry 74: 957–65.CrossRefGoogle ScholarPubMed

MacEwan, JP, Kamat, SA, Duffy, RA, et al. (2016) Hospital readmission rates among patients with schizophrenia treated with long acting injectables or oral antipsychotics. Psychiatr Serv 67: 1183–8.CrossRefGoogle ScholarPubMed

Meyer, JM (2013) Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectrums 18: 58–68.CrossRefGoogle ScholarPubMed

Meyer, JM (2017) Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectrums 22: 17–27.CrossRefGoogle Scholar

Stahl, SM (2014) Long-acting injectable antipsychotics: shall the last be first? CNS Spectrums 19: 3–5.CrossRefGoogle ScholarPubMed

Tiihonen, J, Haukka, J, Taylor, M, et al. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603–9.CrossRefGoogle ScholarPubMed

Berry, MD, Gainetdinov, RR, Hoener, MC, et al. (2017) Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther 180: 161–80.CrossRefGoogle ScholarPubMed

Brannan, S (2020) KarXT (a new mechanism antipsychotic based on xanomeline) is superior to placebo in patients with schizophrenia: phase 2 clinical trial results. Abstract, American Society of Clinical Psychopharmacology Annual Meeting.Google Scholar

Citrome, L (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for the newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 69: 978–97.Google ScholarPubMed

Correll, CU, Davis, RE, Weingart, M, et al. (2020) Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychaitry 77: 349–58.Google ScholarPubMed

Dedic, N, Jones, PG, Hopkins, SC, et al. (2019) SEP363856: a novel psychotropic agent with unique non D₂ receptor mechanism of actions. J Pharmacol Exp Ther 371: 1–14.CrossRefGoogle Scholar

Earley, W, Burgess, MV, Rekeda, L, et al. (2019) Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study, Am J Psychiatry 176: 439–48.CrossRefGoogle ScholarPubMed

Gainetdinov, RR, Hoener, MC, Berry, MD (2018) Trace amines and their receptors. Pharmacol Rev 70: 549–620.CrossRefGoogle ScholarPubMed

Koblan, KS, Kent, J, Hopkins, SC, Krystal, JH, et al. (2020) A non-D₂-receptor-binding drug for the treatment of schizophrenia. New Engl J Med 382: 1407–506.CrossRefGoogle ScholarPubMed

Lieberman, JA, Davis, RE, Correll, CU, et al. (2016) ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry 79: 952–6.CrossRefGoogle ScholarPubMed

Loebel, A, Cucchiaro, J, Silva, R, et al. (2014) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized double-blind, placebo-controlled study. Am J Psychiatry 171: 160–8.Google ScholarPubMed

Loebel, A, Cucchiaro, J, Silva, R, et al. (2014) Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double blind, placebo-controlled study. Am J Psychiatry 171: 169–77.Google ScholarPubMed

Marder, SR, Davis, JM, Couinard, G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the north American trials. J Clin Psychiatry 58: 538–46.CrossRefGoogle ScholarPubMed

McIntyre, RS, Suppes, T, Early, W, Patel, M, Stahl, SM (2020) Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of three randomized, placebo-controlled studies. CNS Spectrums 25: 502–10.CrossRefGoogle Scholar

Meyer, JM, Cummings, MA, Proctor, G, Stahl, SM (2016) Psychopharmacology of persistent violence and aggression. Psychiatr Clin N Am 39: 541–56.CrossRefGoogle ScholarPubMed

Meyer, JM, Stahl, SM (2020) Stahl’s Handbooks: the Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar

Nemeth, G, Laszlovszky, I, Czoboar, P, et al. (2017) Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomized double-blind controlled trial. Lancet 389: 1103–13.CrossRefGoogle Scholar

Pei, Y, Asif-Malik, A, Canales, JJ (2016) Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry and clinical implications. Front Neurosci 10: 148.CrossRefGoogle ScholarPubMed

Perkins, DO, Gu, H, Boteva, K, Lieberman, JA (2005) Relationship between duration of untreated psychosis and outcome in first episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162: 1785–804.CrossRefGoogle ScholarPubMed

Roth, BL. Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate was generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271–2008-00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. For experimental details please refer to the PDSP website http://pdsp.med.unc.edu/Google Scholar

Schwartz, MD, Canales, JJ, Zucci, R, et al. (2018) Trace amine associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets 22: 513–26.CrossRefGoogle ScholarPubMed

Shekar, A, Potter, WZ, Lightfoot, J, et al. (2008) Seletive muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033–9.Google Scholar

Snyder, GL, Vanover, KE, Zhu, H, et al. (2014) Functional profile of a novel modulator of serotonin, dopamine and glutamate neurotransmission. Psychopharmacology 232 : 605–21.Google ScholarPubMed

Stahl, SM (2013) Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectrums 18: 113–17.CrossRefGoogle Scholar

Stahl, SM (2013) Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectrums 18: 285–8.CrossRefGoogle ScholarPubMed

Stahl, SM (2014) Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectrums 19: 279–81.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectrums 21: 1–6.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Mechanism of action of cariprazine. CNS Spectrums 21: 123–7.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT_2A and 5HT_2C receptors. CNS Spectums 21: 271–5.Google ScholarPubMed

Stahl, SM (2017) Drugs for psychosis and mood: unique actions at D₃, D₂, and D₁ dopamine receptor subtypes. CNS Spectrums 22: 375–84.CrossRefGoogle ScholarPubMed

Stahl, SM, Cucchiaro, J, Sinonelli, D, et al. (2013) Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanazapine, or placebo: a 6-month, open-label study. J Clin Psychiatry 74: 507–15.CrossRefGoogle Scholar

Stahl, SM, Laredo, SA, Morrissette, DA (2020) Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Ther Adv Psychopharmacol 10: 1–11.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA, Citrome, L, et al. (2013) “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectrums 18: 150–62.CrossRefGoogle ScholarPubMed

Suppes, T, Silva, R, Cuccharino, J, et al. (2016) Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double blind placebo controlled study. Am J Psychiatry 173: 400–7.CrossRefGoogle ScholarPubMed

Tarazi, F, Stahl, SM (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 13: 1911–22.CrossRefGoogle ScholarPubMed

Thase, ME, Youakim, JM, Skuban, A, et al. (2015) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder. J Clin Psychiatry 76: 1224–31.CrossRefGoogle ScholarPubMed

Zhang, L, Hendrick, JP (2018) The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist. Matters: doi: 10.19185/matters.201712000006.CrossRefGoogle Scholar

Alex, KD, Pehak, EA (2007) Pharmacological mechanisms of serotoninergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296–320.CrossRefGoogle Scholar

Amargos-Bosch, M, Bortolozzi, A, Buig, MV, et al. (2004) Co-expression and in vivo interaction of serotonin 1A and serotonin 2A receptors in pyramidal neurons of prefrontal cortex. Cerbral Cortex 14: 281–99.Google ScholarPubMed

Baez, MV, Cercata, MC, Jerusalinsky, DA (2018) NMDA receptor subunits change after synaptic plasticity induction and learning and memory acquisition. Neural Plast, doi.org/10,1155/2018/5093048.CrossRefGoogle Scholar

Beaulier, JM, Gainetdinov, RR (2011) The physiology, signaling and pharmacology of dopamine receptors. Pharmacol Rev 63: 182–217.CrossRefGoogle Scholar

Belmer, A, Quentin, E, Diaz, SL, et al. (2018) Positive regulation of raphe serotonin neurons by serotonin 2B receptors. Neuropsychopharmacology 42: 1623–32.Google Scholar

Calabresi, P, Picconi, B, Tozzi, A, Ghiglieri, V, Di Fillippo, M (2014) Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neurosci 17: 1022–30.CrossRefGoogle ScholarPubMed

Cathala, A, Devroye, C, Drutel, G, et al. (2019) Serotonin 2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitor control on serotonin neurons. Exp Neurol 311: 57–66.CrossRefGoogle ScholarPubMed

De Bartolomeis, A, Fiore, G, Iasevoli, F (2005) Dopamine glutamate interaction and antipsychotics mechanism of action: implication for new pharmacologic strategies in psychosis. Curr Pharmaceut Design 11: 3561–94.CrossRefGoogle ScholarPubMed

DeLong, MR, Wichmann, T (2007) Circuits and Ciruit disorders of the basal ganglia. Arch Neurol 64: 20–4.CrossRefGoogle Scholar

Fink, KB, Gothert, M (2007) 5HT receptor regulation of neurotransmitter release. Pharmacol Rev 59: 360–417.CrossRefGoogle ScholarPubMed

Hansen, KB, Yi, F, Perszyk, RE, et al (2018) Structure, function and allosteric modulation of NMDA receptors. J Gen Physiol 150: 1081–105.CrossRefGoogle ScholarPubMed

Homayoun, H, Moghaddam, B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496–500.CrossRefGoogle ScholarPubMed

Nicoll, RA (2017) A brief history of long-term potentiation. Neuron 93: 281–99.CrossRefGoogle ScholarPubMed

Paoletti, P, Neyton, J (2007) NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7: 39–47.CrossRefGoogle ScholarPubMed

Scheefhals, N, MacGillavry, HD (2018) Functional organization of postsynaptic glutamate receptors. Mol Cell Neurosci 91: 82–94.CrossRefGoogle ScholarPubMed

Sokoloff, P, Le Foil, B (2017) The dopamine D₃ receptor: a quarter century later. Eur J Neurosci 45: 2–19.CrossRefGoogle ScholarPubMed

Stahl, SM (2017) Dazzled by the dominions of dopamine: clinical roles of D₃, D₂, and D₁ receptors. CNS Spectrums 22: 305–11.CrossRefGoogle ScholarPubMed

Aghajanian, GK, Marek, GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31: 302–12.CrossRefGoogle ScholarPubMed

Bloomfield, MAP, Morgan, CJA, Egerton, A, et al. (2014) Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75: 470–8.CrossRefGoogle ScholarPubMed

Brugger, SP, Anelescu, I, Abi-Dargham, A, et al. (2020) Heterogeneity and striatal dopamine function in schizophrenia: meta analysis of variance. Biol Psychiatry 67: 215–24.Google Scholar

Bubenikova-Valesova, V, Horacek, J, Vrajova, M, et al. (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32: 1014–23.CrossRefGoogle ScholarPubMed

Demjaha, A, Murray, RM, McGuire, PK (2012) Dopamine synthesis capacity in patients with treatment resistant schizophrenia. Am J Psychiatry 169: 1203–10.CrossRefGoogle ScholarPubMed

Driesen, N, McCarthy, G, Bhagwagar, Z, et al (2013) The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacol 38: 2613–22.CrossRefGoogle ScholarPubMed

Egerton, A, Chaddock, CA, Winton-Brown, TT, et al. (2013) Presynaptic striatal dopamine dysfunction in people at ultra high risk for psychosis: findings in a second cohort. Biol Psychiatry 74: 106–12.CrossRefGoogle ScholarPubMed

Gellings Lowe, N, Rapagnani, MP, Mattei, C, Stahl, SM (2012)The psychopharmacology of hallucinations: ironic insights into mechanisms of action. In The Neuroscience of Hallucinations, Jardri, R, Thomas, P, Cachia, A and Pins, D. (eds.), Berlin: Springer, 471–92.Google Scholar

Howes, OD, Bose, SK, Turkheimer, F, et al. (2011) Dopamine synthsis capacity before onset of psychosis: a prospective ¹⁸F-DOPA PET imaging study. Am J Psychiatry 169: 1311–17.Google Scholar

Howes, OD, Montgomery, AJ, Asselin, MC, et al. (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13–20.CrossRefGoogle ScholarPubMed

Juahar, S, Nour, MM, Veronese, M, et al. (2017) A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 74: 1206–13.Google Scholar

Lodge, DJ, Grace, AA (2011) Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 32: 507–13.CrossRefGoogle ScholarPubMed

McCutcheon, RA, Abi-Dargham, A, Howes, OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42: 205–20.CrossRefGoogle ScholarPubMed

Mizrahi, R, Kenk, M, Suridjan, I, et al (2014) Stress induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39: 1479–89.CrossRefGoogle ScholarPubMed

Paz, RD, Tardito, S, Atzori, M (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 18: 773–86.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Parkinson’s disease psychosis as a serotonin–dopamine imbalance syndrome. CNS Spectrums 21: 355–9.CrossRefGoogle ScholarPubMed

Stahl, SM (2018) Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectrums 23: 187–91.CrossRefGoogle ScholarPubMed

Weinstein, JJ, Chohan, MO, Slifstein, M, et al. (2017) Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry 81: 31–42.CrossRefGoogle ScholarPubMed

Alphs, LD, Summerfelt, A, Lann, H, Muller, RJ (1989) The Negative Symptom Assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 25: 159–63.Google ScholarPubMed

Arango, C, Rapado-Castro, M, Reig, S, et al. (2012) Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry 69: 16–26.CrossRefGoogle ScholarPubMed

Cruz, DA, Weawver, CL, Lovallo, EM, Melchitzky, DS, Lewis, DA. (2009) Selective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia. Neuropsychopharmacology 34: 2112–24.CrossRefGoogle ScholarPubMed

Dragt, S, Nieman, DH, Schultze-Lutter, F, et al. (2012) Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand 125: 45–53.CrossRefGoogle ScholarPubMed

Eisenberg, DP, Berman, KF (2010) Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 35: 258–77.CrossRefGoogle ScholarPubMed

Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ (2010) Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 167: 987–93.CrossRefGoogle ScholarPubMed

Fusar-Poli, P, Bonoldi, I, Yung, AR, et al. (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69: 220–9.CrossRefGoogle ScholarPubMed

Goff, DC, Zeng, B, Ardelani, BA, et al. (2018) Association of hippocampal atrophy with duration of untreated psychosis and molecular biomarkers during initial antipsychotic treatment of first episode psychosis. JAMA Psychiatry 75: 370–8.CrossRefGoogle ScholarPubMed

Henry, LP, Amminger, GP, Harris, MG, et al. (2010) The EPPIC follow up study of first episode psychosis: longer term clinical and functional outcome 7 years after index admission. J Clin Psychiatry 71: 716–28.CrossRefGoogle ScholarPubMed

Kane, JM, Robinson, DG, Schooler, NR, et al. (2016) Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 173: 362–72.CrossRefGoogle ScholarPubMed

Kendler, KS, Ohlsson, H, Sundquist, J, et al. (2019) Prediction of onset of substance induced psychotic disorder and its progression to schizophrenia in a Swedish National Sample. Am J Psychiatry 176: 711–19.CrossRefGoogle Scholar

Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O (2011) Cannabis use and earlier onset of psychosis. Arch Gen Psychiatry 68: 555–61.CrossRefGoogle ScholarPubMed

Lieberman, JA, Small, SA, Girgis, RR (2019) Early detection and preventive intervention in schizophrenia: from fantasy to reality. Am J Psychiatry 176: 794–810.CrossRefGoogle ScholarPubMed

Mechelli, A, Riecher-Rossler, A, Meisenzahl, EM, et al. (2011) Neuroanatomical abnormalities that predate the onset of psychosis. Arch Gen Psychiatry 68: 489–95.CrossRefGoogle ScholarPubMed

Morrissette, DA, Stahl, SM (2014) Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectrums 19: 439–48.CrossRefGoogle ScholarPubMed

Stahl, SM (2014) Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectrums 19: 357–65.CrossRefGoogle ScholarPubMed

Stahl, SM (2015) Is impulsive violence an addiction? The habit hypothesis. CNS Spectrums 20: 165–9.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA, Cummings, M (2014) California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectrums 19: 449–65.CrossRefGoogle ScholarPubMed

Wykes, T, Huddy, V, Cellard, C, McGurk, SR, Czobar, P (2011) A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 168: 472–85.CrossRefGoogle ScholarPubMed

Artukoglu, BB, Li, F, Szejko, N, et al. (2020) Pharmacologic treatment of tardive dyskinesia: a meta analysis and systematic review. J Clin Psychiatry 81: e1–11.CrossRefGoogle ScholarPubMed

Bhidayasin, R, Jitkretsandakul, O, Friedman, JH (2018) Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 389: 67–75.CrossRefGoogle Scholar

Carbon, M, Kane, JM, Leucht, S, et al. (2018) Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta analysis. World Psychiatry 173: 330–40.Google Scholar

Citrome, L (2017) Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Practice, doi.org 10.1111/ijcp.12964.CrossRefGoogle Scholar

Citrome, L (2017) Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Practice, doi.org 10.1111/ijcp.13030.CrossRefGoogle Scholar

Jacobsen, FM (2015) Second generation antipsychotics and tardive syndromes in affective illness: a public health problem with neuropsychiatric consequences. Am J Public Health 105: e10–16.CrossRefGoogle ScholarPubMed

Niemann, N, Jankovic, J (2018) Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 78: 525–41.Google ScholarPubMed

Stahl, SM (2017) Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum. CNS Spectrums 22: 427–34.CrossRefGoogle ScholarPubMed

Stahl, SM (2018) Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects. CNS Spectrums 23: 1–6.CrossRefGoogle ScholarPubMed

Stahl, SM (2018) Comparing pharmacological mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectrums 23: 239–47.CrossRefGoogle ScholarPubMed

Woods, SW, Morgenstern, H, Saksa, JR, et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71: 463–74.CrossRefGoogle ScholarPubMed

Brissos, S, Veguilla, MR, Taylor, D, et al. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 4: 198–219.CrossRefGoogle ScholarPubMed

Kishimoto, T, Nitto, M, Borenstein, M, et al. (2013) Long acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta analysis of mirror image studies. J Clin Psychiatry 74: 957–65.CrossRefGoogle ScholarPubMed

MacEwan, JP, Kamat, SA, Duffy, RA, et al. (2016) Hospital readmission rates among patients with schizophrenia treated with long acting injectables or oral antipsychotics. Psychiatr Serv 67: 1183–8.CrossRefGoogle ScholarPubMed

Meyer, JM (2013) Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectrums 18: 58–68.CrossRefGoogle ScholarPubMed

Meyer, JM (2017) Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectrums 22: 17–27.CrossRefGoogle Scholar

Stahl, SM (2014) Long-acting injectable antipsychotics: shall the last be first? CNS Spectrums 19: 3–5.CrossRefGoogle ScholarPubMed

Tiihonen, J, Haukka, J, Taylor, M, et al. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603–9.CrossRefGoogle ScholarPubMed

Berry, MD, Gainetdinov, RR, Hoener, MC, et al. (2017) Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther 180: 161–80.CrossRefGoogle ScholarPubMed

Brannan, S (2020) KarXT (a new mechanism antipsychotic based on xanomeline) is superior to placebo in patients with schizophrenia: phase 2 clinical trial results. Abstract, American Society of Clinical Psychopharmacology Annual Meeting.Google Scholar

Citrome, L (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for the newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 69: 978–97.Google ScholarPubMed

Correll, CU, Davis, RE, Weingart, M, et al. (2020) Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychaitry 77: 349–58.Google ScholarPubMed

Dedic, N, Jones, PG, Hopkins, SC, et al. (2019) SEP363856: a novel psychotropic agent with unique non D₂ receptor mechanism of actions. J Pharmacol Exp Ther 371: 1–14.CrossRefGoogle Scholar

Earley, W, Burgess, MV, Rekeda, L, et al. (2019) Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study, Am J Psychiatry 176: 439–48.CrossRefGoogle ScholarPubMed

Gainetdinov, RR, Hoener, MC, Berry, MD (2018) Trace amines and their receptors. Pharmacol Rev 70: 549–620.CrossRefGoogle ScholarPubMed

Koblan, KS, Kent, J, Hopkins, SC, Krystal, JH, et al. (2020) A non-D₂-receptor-binding drug for the treatment of schizophrenia. New Engl J Med 382: 1407–506.CrossRefGoogle ScholarPubMed

Lieberman, JA, Davis, RE, Correll, CU, et al. (2016) ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry 79: 952–6.CrossRefGoogle ScholarPubMed

Loebel, A, Cucchiaro, J, Silva, R, et al. (2014) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized double-blind, placebo-controlled study. Am J Psychiatry 171: 160–8.Google ScholarPubMed

Loebel, A, Cucchiaro, J, Silva, R, et al. (2014) Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double blind, placebo-controlled study. Am J Psychiatry 171: 169–77.Google ScholarPubMed

Marder, SR, Davis, JM, Couinard, G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the north American trials. J Clin Psychiatry 58: 538–46.CrossRefGoogle ScholarPubMed

McIntyre, RS, Suppes, T, Early, W, Patel, M, Stahl, SM (2020) Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of three randomized, placebo-controlled studies. CNS Spectrums 25: 502–10.CrossRefGoogle Scholar

Meyer, JM, Cummings, MA, Proctor, G, Stahl, SM (2016) Psychopharmacology of persistent violence and aggression. Psychiatr Clin N Am 39: 541–56.CrossRefGoogle ScholarPubMed

Meyer, JM, Stahl, SM (2020) Stahl’s Handbooks: the Clozapine Handbook. Cambridge: Cambridge University Press.Google Scholar

Nemeth, G, Laszlovszky, I, Czoboar, P, et al. (2017) Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomized double-blind controlled trial. Lancet 389: 1103–13.CrossRefGoogle Scholar

Pei, Y, Asif-Malik, A, Canales, JJ (2016) Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry and clinical implications. Front Neurosci 10: 148.CrossRefGoogle ScholarPubMed

Perkins, DO, Gu, H, Boteva, K, Lieberman, JA (2005) Relationship between duration of untreated psychosis and outcome in first episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162: 1785–804.CrossRefGoogle ScholarPubMed

Roth, BL. Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate was generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271–2008-00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. For experimental details please refer to the PDSP website http://pdsp.med.unc.edu/Google Scholar

Schwartz, MD, Canales, JJ, Zucci, R, et al. (2018) Trace amine associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets 22: 513–26.CrossRefGoogle ScholarPubMed

Shekar, A, Potter, WZ, Lightfoot, J, et al. (2008) Seletive muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033–9.Google Scholar

Snyder, GL, Vanover, KE, Zhu, H, et al. (2014) Functional profile of a novel modulator of serotonin, dopamine and glutamate neurotransmission. Psychopharmacology 232 : 605–21.Google ScholarPubMed

Stahl, SM (2013) Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectrums 18: 113–17.CrossRefGoogle Scholar

Stahl, SM (2013) Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectrums 18: 285–8.CrossRefGoogle ScholarPubMed

Stahl, SM (2014) Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectrums 19: 279–81.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectrums 21: 1–6.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Mechanism of action of cariprazine. CNS Spectrums 21: 123–7.CrossRefGoogle ScholarPubMed

Stahl, SM (2016) Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT_2A and 5HT_2C receptors. CNS Spectums 21: 271–5.Google ScholarPubMed

Stahl, SM (2017) Drugs for psychosis and mood: unique actions at D₃, D₂, and D₁ dopamine receptor subtypes. CNS Spectrums 22: 375–84.CrossRefGoogle ScholarPubMed

Stahl, SM, Cucchiaro, J, Sinonelli, D, et al. (2013) Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanazapine, or placebo: a 6-month, open-label study. J Clin Psychiatry 74: 507–15.CrossRefGoogle Scholar

Stahl, SM, Laredo, SA, Morrissette, DA (2020) Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Ther Adv Psychopharmacol 10: 1–11.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA, Citrome, L, et al. (2013) “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectrums 18: 150–62.CrossRefGoogle ScholarPubMed

Suppes, T, Silva, R, Cuccharino, J, et al. (2016) Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double blind placebo controlled study. Am J Psychiatry 173: 400–7.CrossRefGoogle ScholarPubMed

Tarazi, F, Stahl, SM (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 13: 1911–22.CrossRefGoogle ScholarPubMed

Thase, ME, Youakim, JM, Skuban, A, et al. (2015) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder. J Clin Psychiatry 76: 1224–31.CrossRefGoogle ScholarPubMed

Zhang, L, Hendrick, JP (2018) The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist. Matters: doi: 10.19185/matters.201712000006.CrossRefGoogle Scholar

Alvarez, LD, Pecci, A, Estrin, DA (2019) In searach of GABA A receptor’s neurosteroid binding sites. J Med Chem 62: 5250–60.CrossRefGoogle Scholar

Belelli, D, Hogenkamp, D, Gee, KW, et al. (2020) Realising the therapeutic potential of neuroactive steroid modulators of the GABA A receptor. Neurobiol Stress 12: 100207.CrossRefGoogle ScholarPubMed

Botella, GM, Salitur, FG, Harrison, BL, et al. (2017) Neuroactive steroids. 2. 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1ʹ-yl)-19-nor-5β-pregnan-20-one (SAGE 217): a clinical next generation neuroactive steroid positive allosteric modulator of the GABA A receptor. J Med Chem 60: 7810–19.Google Scholar

Chen, ZW, Bracomonies, JR, Budelier, MM, et al. (2019) Multiple functional neurosteroid binding sites on GABA A receptors. PLOS Biol 17: e3000157; doi.org/10.137/journal.pbio.3000157.CrossRefGoogle Scholar

Gordon, JL, Girdler, SS, Meltzer-Brody, SE, et al. (2015) Ovarian hormone fluctuation, neurosteroids and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry 172: 227–36.CrossRefGoogle ScholarPubMed

Gunduz-Bruce, H, Silber, C, Kaul, I, et al. (2019) Trial of SAGE 217 in patients with major depressive disorder. New Engl J Med 381: 903–11.CrossRefGoogle ScholarPubMed

Luscher, B, Mohler, H (2019) Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster reliance. F1000Research 8: 751.CrossRefGoogle Scholar

Marek, GJ, Aghajanian, GK (1996) Alpha 1B-adrenoceptor-mediated excitation of piriform cortical interneurons. Eur J Pharmacol 305: 95–100.CrossRefGoogle ScholarPubMed

Marek, GJ, Aghajanian, GK (1999) 5HT_2A receptor or alpha 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367: 197–206.CrossRefGoogle ScholarPubMed

Meltzer-Brody, S, Kanes, SJ (2020) Allopregnanolone in postpartum depression: role in pathophysiology and treatment. Neurobiol Stress 12: 100212.CrossRefGoogle Scholar

Pieribone, VA, Nicholas, AP, Dagerlind, A, et al. (1994) Distribution of alpha 1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype specific probes. J Neurosci 14: 4252–68.CrossRefGoogle ScholarPubMed

Price, DT, Lefkowitz, RJ, Caron, MG, et al. (1994) Localization of mRNA for three distinct alpha1 adrenergic receptor sybtypes in human tissues: implications for human alpha adrenergic physiology. Mol Pharmacol 45: 171–5.Google Scholar

Ramos, BP, Arnsten, AFT (2007) Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 113: 523–36.CrossRefGoogle ScholarPubMed

Santana, N, Mengod, G, Artigas, F (2013) Expression of alpha1 adrenergic receptors in rat prefrontal cortex: cellular colocalization with 5HT_2A receptors. Int J Neuropsychopharmacol 16: 1139–51.CrossRefGoogle Scholar

Zorumski, CF, Paul, SM, Covey, DF, et al. (2019) Neurosteroids as novel antidepressants and anxiolytics: GABA A receptors and beyond. Neurobiol Stress 11: 100196.CrossRefGoogle ScholarPubMed

Bergink, V, Bouvy, PF, Vervoort, JSP, et al. (2012) Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 169: 609–16.CrossRefGoogle ScholarPubMed

Bogdan, R, Williamson, DE, Hariri, AR. (2012) Mineralocorticoid receptor Iso/Val (rs5522) genotype moderates the association between previous childhood emotional neglect and amygdala reactivity. Am J Psychiatry 169: 515–22.CrossRefGoogle ScholarPubMed

Brites, D, Fernandes, A (2015) Neuroinflammation and depression: microglia activion, extracellular microvesicles and micro RNA dysregulation. Front Cell Neurosci 9: 476.CrossRefGoogle Scholar

Fiedorowicz, JG, Endicott, J, Leon, AC, et al. (2011) Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 168: 40–8.CrossRefGoogle ScholarPubMed

Goldberg, JF, Perlis, RH, Bowden, CL, et al. (2009) Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry 166: 173–81.CrossRefGoogle ScholarPubMed

McIntyre, RS, Anderson, N, Baune, BT, et al. (2019) Expert consensus on screening assessment of cognition in psychiatry. CNS Spectrums 24: 154–62.CrossRefGoogle ScholarPubMed

Price, JL, Drevets, WC (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology 35: 192–216.CrossRefGoogle ScholarPubMed

Rao, U, Chen, LA, Bidesi, AS, et al. (2010) Hippocampal changes associated with early-life adversity and vulnerability to depression. Biol Psychiatry 67: 357–64.CrossRefGoogle ScholarPubMed

Roiser, JP, Elliott, R, Sahakian, BJ (2012) Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 37: 117–36.CrossRefGoogle ScholarPubMed

Roiser, JP, Sahakian, BJ (2013) Hot and cold cognition in depression. CNS Spectrums 18: 139–49.CrossRefGoogle ScholarPubMed

Roy, A, Gorodetsky, E, Yuan, Q, Goldman, D, Enoch, MA (2010) Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 35: 1674–83.CrossRefGoogle ScholarPubMed

Semkovska, M, Quinlivan, L, Ogrady, T, et al. (2019) Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry 6: 851–61.CrossRefGoogle Scholar

Stahl, SM (2017) Psychiatric pharmacogenomics: how to integrate into clinical practice. CNS Spectrums 22: 1–4.CrossRefGoogle ScholarPubMed

Stahl, SM (2017) Mixed-up about how to diagnose and treat mixed features in major depressive episodes. CNS Spectrums 22: 111–15.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA (2017) Does a “whiff” of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Bipolar Disord 19: 595–6.CrossRefGoogle Scholar

Stahl, SM, Morrissette, DA (2019) Mixed mood states: baffled, bewildered, befuddled and bemused.Bipolar Disord 21: 560–1.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA, Faedda, G, et al. (2017) Guidelines for the recognition and management of mixed depression. CNS Spectrums 22: 203–19.CrossRefGoogle ScholarPubMed

Yatham, LN, Liddle, PF, Sossi, V, et al. (2012) Positron emission tomography study of the effects of tryptophan depletion on brain serotonin₂ receptors in subjects recently remitted from major depression. Arch Gen Psychiatry 69: 601–9.CrossRefGoogle ScholarPubMed

Aan het Rot, M, Collins, KA, Murrough, JW, et al. (2010) Safety and efficacy of repeated dose intravenous ketamine for treatment resistant depression. Biol Psychiatry 67: 139–45.CrossRefGoogle ScholarPubMed

Abdallah, CG, DeFeyter, HM, Averill, LA, et al. (2018) The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43: 2154–60.CrossRefGoogle ScholarPubMed

Anderson, A, Iosifescu, DV, Macobsen, M, et al. (2019) Efficacy and safety of AXS-05, an oral NMDA receptor antagonist with multimodal activity, in major depressive disorder: results of a phase 2, double blind active controlled trial. Abstract, American Society of Clincal Psychopharmacology Annual Meeting.Google Scholar

Deyama, S, Bang, E, Wohleb, ES, et al. (2019) Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine. Am J Psychiatry 176: 388-400.CrossRefGoogle ScholarPubMed

DiazGranados, N, Ibrahim, LA, Brutsche, NE, et al. (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant depressive disorder. J Clin Psychiatry 71: 1605–11.CrossRefGoogle Scholar

Duman, RS, Voleti, B (2012) Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35: 47–56.CrossRefGoogle ScholarPubMed

Dwyer, JM, Duman, RS (2013) Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid acting antidepressants. Biol Psychiatry 73: 1189–98.CrossRefGoogle ScholarPubMed

Fu, DJ, Ionescu, DF, Li, X, et al. (2020) Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double blind randomized study (ASPIRE K). J Clin Psychiatry 61: doi.org/10.4088/JCP.19m13191.Google Scholar

Hanania, T, Manfredi, P, Inturrisi, C, et al. (2020) The NMDA antagonist dextromethadone acutely improves depressive like behavior in the forced swim test performance of rats. AA Rev Public Health 34: 119–38.Google Scholar

Hasler, G (2020) Toward specific ways to combine ketamine and psychotherapy in treating depression. CNS Spectrums 25: 445–7.CrossRefGoogle ScholarPubMed

Ibrahim, L, Diaz Granados, N, Franco-Chaves, J (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526–33.CrossRefGoogle ScholarPubMed

Li, N, Lee, Lin RJ, et al. (2010) mTor-dependent synapse formation underlies the rapid antidepressant effects of NMDA antgonists. Science 329: 959–64.CrossRefGoogle Scholar

Monteggia, LM, Gideons, E, Kavalali, EG (2013) The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73: 1199–203.CrossRefGoogle ScholarPubMed

Mosa-Sava, RN, Murdock, MH, Parekh, PK, et al. (2019) Sustained rescue of prefrontal circuit dysfunction by antidepressant induced spine formation. Science 364: doi: 10.1126/Science.aat80732019.Google Scholar

Murrough, JW, Perez, AM, Pillemer, S, et al. (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment resistant major depression. Biol Psychiatry 74: 250–6.CrossRefGoogle ScholarPubMed

O’Gorman, C, Iosifescu, DV, Jones, A, et al. (2018) Clinical development of AXS-05 for treatment resistant depression and agitation associated with Alzheimer’s disease. Abstract, American Society of Clinical Psychopharmacology Annual Meeting.Google Scholar

O’Gorman, C, Jones, A, Iosifescu, DV, et al. (2020) Efficacy and safety of AXS-05, an oral NMDA receptor antagonist with multimodal activity in major depressive disorder: results from the GEMINI phase 3, double blind placebo-controlled trial. Abstract, American Society of Clinical Psychopharmacology Annual Meeting.CrossRefGoogle Scholar

Phillips, JL, Norris, S, Talbot, J, et al. (2019) Single, repeated and maintenance ketamine infusions for treatment resistant depression: a randomized controlled trial. Am J Psychiatry 176: 401–9.CrossRefGoogle ScholarPubMed

Price, RB, Nock, MK, Charney, DS, Mathew, SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522–6.CrossRefGoogle ScholarPubMed

Salvadore, G, Cornwell, BR, Sambataro, F, et al. (2010) Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35: 1415–22.CrossRefGoogle Scholar

Stahl, SM (2013) Mechanism of action of ketamine. CNS Spectrums 18: 171–4.Google ScholarPubMed

Stahl, SM (2013) Mechanism of action of dextromethorphan/quinidine: comparison with ketamine. CNS Spectrums 18: 225–7.Google ScholarPubMed

Stahl, SM (2016) Dextromethorphan–quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? CNS Spectrums 21: 419–23.CrossRefGoogle ScholarPubMed

Stahl, SM (2019) Mechanism of action of dextromethorphan/bupropion: a novel NMDA antagonist with multimodal activity. CNS Spectrums 24: 461–6.CrossRefGoogle ScholarPubMed

Wajs, E, Aluisio, L, Holder, R, et al. (2020) Esketamine nasal spray plus oral antidepressant in patients with treatment resistant depression: assessment of long term safety in a phase 3 open label study (SUSTAIN2). J Clin Psychiatry 81: 19m12891.CrossRefGoogle Scholar

Williams, NR, Heifets, B, Blasey, C, et al. (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175: 1205–15CrossRefGoogle ScholarPubMed

Zarate, Jr. CA, Brutsche, NE, Ibrahim, L (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71: 939–46.CrossRefGoogle ScholarPubMed

Alvarez, E, Perez, V, Dragheim, M, Loft, H, Artigas, F (2012) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15: 589–600.CrossRefGoogle ScholarPubMed

BALANCE investigators and collaborators, et al. (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomized open-label trial. Lancet 375: 385–95.Google Scholar

Baldessarini, RJ, Tondo, L, Vazquez, GH (2019) Pharmacological treatment of adult bipolar disorder. Mol Psychiatry 24: 198–217.CrossRefGoogle ScholarPubMed

Bang-Andersen, B, Ruhland, T, Jorgensen, M, et al. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl] piperazine (LuAA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54: 3206–21.CrossRefGoogle ScholarPubMed

Carhart-Harris, RL, Bolstridge, M, Day, CMG, et al. (2018) Psilocybin with psychological support for treatment-resistant depression: six month follow up. Psychopharmacology 235: 399–408.CrossRefGoogle ScholarPubMed

Carhart-Harris, RL, Bolstridge, M, Rucker, J, et al. (2016) Psilocybin with psychological support for treatment resistant depression: an open label feasibility study. Lancet Psychiatry 3: 619–27.CrossRefGoogle ScholarPubMed

Carhart-Harris, RL, Goodwin, GM (2017) The therapeutic potential of psychedelic drugs: past, present and future, Neuropsychopharmacology 42: 2105–13.CrossRefGoogle ScholarPubMed

Carhart-Harris, RL, Leech, R, Williams, TM, et al. (2012) Implications for psychedelic assisted psychotherapy: a functional magnetic resonance imaging study with psilocybin. Br J Psychiatry: doi:10.1192/bjp.bp.111.103309.CrossRefGoogle Scholar

Chiu, CT, Chuan, DM (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128: 281–304.CrossRefGoogle ScholarPubMed

Cipriani, A, Pretty, H, Hawton, K, Geddes, JR (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162: 1805–19.CrossRefGoogle ScholarPubMed

Frye, MA, Grunze, H, Suppes, T, et al. (2007) A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 164: 1242–9.CrossRefGoogle ScholarPubMed

Grady, M, Stahl, SM (2012) Practical guide for prescribing MAOI: Debunking myths and removing barriers. CNS Spectrums 17: 2–10.CrossRefGoogle Scholar

Mork, A, Pehrson, A, Brennum, LT, et al. (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340: 666–75.CrossRefGoogle ScholarPubMed

Pasquali, L, Busceti, CL, Fulceri, F, Paparelli, A, Fornai, F (2010) Intracellular pathways underlying the effects of lithium. Behav Pharmacol 21: 473–92.CrossRefGoogle ScholarPubMed

Perlis, RH, Ostacher, MJ, Goldberg, JF, et al. (2010) Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 35: 2545–52.CrossRefGoogle ScholarPubMed

Pompili, M, Vazquez, GH, Forte, A, Morrissette, DA, Stahl, SM (2020) Pharmacological treatment of mixed states. Psychiatr Clin N Am 43: 157–86. doi:10.1016/j.psc.2019.10.015CrossRefGoogle ScholarPubMed

Schwartz, TL, Siddiqui, US, Stahl, SM (2011) Vilazodone: a brief pharmacologic and clinical review of the novel SPARI (serotonin partial agonist and reuptake inhibitor). Ther Adv Psychopharmacol 1: 81–7.CrossRefGoogle ScholarPubMed

Settimo, L, Taylor, D (2018) Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. J Psychopharmacol 32: 960104.CrossRefGoogle ScholarPubMed

Stahl, SM (2009) Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums 14: 536–46.CrossRefGoogle ScholarPubMed

Stahl, SM (2012) Psychotherapy as an epigenetic “drug”: psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. J Clin Pharm Ther 37: 249–53.CrossRefGoogle ScholarPubMed

Stahl, SM (2014) Mechanism of action of the SPARI vilazodone: (serotonin partial agonist reuptake inhibitor). CNS Spectrums 19: 105–9.CrossRefGoogle ScholarPubMed

Stahl, SM (2014) Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectrums 19: 207–12.CrossRefGoogle ScholarPubMed

Stahl, SM (2015) Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT_1A, 5HT_1B, 5HT_1D, 5HT₇ receptors). CNS Spectrums 20: 93–7.CrossRefGoogle ScholarPubMed

Stahl, SM (2015) Modes and nodes explain the mechanism of action of vortioxetine, multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectrums 20: 515–19.Google ScholarPubMed

Stahl, SM, Fava, M, Trivedi, M (2010) Agomelatine in the treatment of major depressive disorder: an 8 week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 71: 616–26.CrossRefGoogle ScholarPubMed

Undurraga, J, Baldessarini, RJ, Valenti, M, et al. (2012) Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord 139: 89–93.CrossRefGoogle ScholarPubMed

Zajecka, J, Schatzberg, A, Stahl, SM, et al. (2010) Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30: 135–44.CrossRefGoogle ScholarPubMed

Alvarez, LD, Pecci, A, Estrin, DA (2019) In searach of GABA A receptor’s neurosteroid binding sites. J Med Chem 62: 5250–60.CrossRefGoogle Scholar

Belelli, D, Hogenkamp, D, Gee, KW, et al. (2020) Realising the therapeutic potential of neuroactive steroid modulators of the GABA A receptor. Neurobiol Stress 12: 100207.CrossRefGoogle ScholarPubMed

Botella, GM, Salitur, FG, Harrison, BL, et al. (2017) Neuroactive steroids. 2. 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1ʹ-yl)-19-nor-5β-pregnan-20-one (SAGE 217): a clinical next generation neuroactive steroid positive allosteric modulator of the GABA A receptor. J Med Chem 60: 7810–19.Google Scholar

Chen, ZW, Bracomonies, JR, Budelier, MM, et al. (2019) Multiple functional neurosteroid binding sites on GABA A receptors. PLOS Biol 17: e3000157; doi.org/10.137/journal.pbio.3000157.CrossRefGoogle Scholar

Gordon, JL, Girdler, SS, Meltzer-Brody, SE, et al. (2015) Ovarian hormone fluctuation, neurosteroids and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psychiatry 172: 227–36.CrossRefGoogle ScholarPubMed

Gunduz-Bruce, H, Silber, C, Kaul, I, et al. (2019) Trial of SAGE 217 in patients with major depressive disorder. New Engl J Med 381: 903–11.CrossRefGoogle ScholarPubMed

Luscher, B, Mohler, H (2019) Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster reliance. F1000Research 8: 751.CrossRefGoogle Scholar

Marek, GJ, Aghajanian, GK (1996) Alpha 1B-adrenoceptor-mediated excitation of piriform cortical interneurons. Eur J Pharmacol 305: 95–100.CrossRefGoogle ScholarPubMed

Marek, GJ, Aghajanian, GK (1999) 5HT_2A receptor or alpha 1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367: 197–206.CrossRefGoogle ScholarPubMed

Meltzer-Brody, S, Kanes, SJ (2020) Allopregnanolone in postpartum depression: role in pathophysiology and treatment. Neurobiol Stress 12: 100212.CrossRefGoogle Scholar

Pieribone, VA, Nicholas, AP, Dagerlind, A, et al. (1994) Distribution of alpha 1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype specific probes. J Neurosci 14: 4252–68.CrossRefGoogle ScholarPubMed

Price, DT, Lefkowitz, RJ, Caron, MG, et al. (1994) Localization of mRNA for three distinct alpha1 adrenergic receptor sybtypes in human tissues: implications for human alpha adrenergic physiology. Mol Pharmacol 45: 171–5.Google Scholar

Ramos, BP, Arnsten, AFT (2007) Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 113: 523–36.CrossRefGoogle ScholarPubMed

Santana, N, Mengod, G, Artigas, F (2013) Expression of alpha1 adrenergic receptors in rat prefrontal cortex: cellular colocalization with 5HT_2A receptors. Int J Neuropsychopharmacol 16: 1139–51.CrossRefGoogle Scholar

Zorumski, CF, Paul, SM, Covey, DF, et al. (2019) Neurosteroids as novel antidepressants and anxiolytics: GABA A receptors and beyond. Neurobiol Stress 11: 100196.CrossRefGoogle ScholarPubMed

Bergink, V, Bouvy, PF, Vervoort, JSP, et al. (2012) Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 169: 609–16.CrossRefGoogle ScholarPubMed

Bogdan, R, Williamson, DE, Hariri, AR. (2012) Mineralocorticoid receptor Iso/Val (rs5522) genotype moderates the association between previous childhood emotional neglect and amygdala reactivity. Am J Psychiatry 169: 515–22.CrossRefGoogle ScholarPubMed

Brites, D, Fernandes, A (2015) Neuroinflammation and depression: microglia activion, extracellular microvesicles and micro RNA dysregulation. Front Cell Neurosci 9: 476.CrossRefGoogle Scholar

Fiedorowicz, JG, Endicott, J, Leon, AC, et al. (2011) Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 168: 40–8.CrossRefGoogle ScholarPubMed

Goldberg, JF, Perlis, RH, Bowden, CL, et al. (2009) Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry 166: 173–81.CrossRefGoogle ScholarPubMed

McIntyre, RS, Anderson, N, Baune, BT, et al. (2019) Expert consensus on screening assessment of cognition in psychiatry. CNS Spectrums 24: 154–62.CrossRefGoogle ScholarPubMed

Price, JL, Drevets, WC (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology 35: 192–216.CrossRefGoogle ScholarPubMed

Rao, U, Chen, LA, Bidesi, AS, et al. (2010) Hippocampal changes associated with early-life adversity and vulnerability to depression. Biol Psychiatry 67: 357–64.CrossRefGoogle ScholarPubMed

Roiser, JP, Elliott, R, Sahakian, BJ (2012) Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 37: 117–36.CrossRefGoogle ScholarPubMed

Roiser, JP, Sahakian, BJ (2013) Hot and cold cognition in depression. CNS Spectrums 18: 139–49.CrossRefGoogle ScholarPubMed

Roy, A, Gorodetsky, E, Yuan, Q, Goldman, D, Enoch, MA (2010) Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 35: 1674–83.CrossRefGoogle ScholarPubMed

Semkovska, M, Quinlivan, L, Ogrady, T, et al. (2019) Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry 6: 851–61.CrossRefGoogle Scholar

Stahl, SM (2017) Psychiatric pharmacogenomics: how to integrate into clinical practice. CNS Spectrums 22: 1–4.CrossRefGoogle ScholarPubMed

Stahl, SM (2017) Mixed-up about how to diagnose and treat mixed features in major depressive episodes. CNS Spectrums 22: 111–15.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA (2017) Does a “whiff” of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Bipolar Disord 19: 595–6.CrossRefGoogle Scholar

Stahl, SM, Morrissette, DA (2019) Mixed mood states: baffled, bewildered, befuddled and bemused.Bipolar Disord 21: 560–1.CrossRefGoogle ScholarPubMed

Stahl, SM, Morrissette, DA, Faedda, G, et al. (2017) Guidelines for the recognition and management of mixed depression. CNS Spectrums 22: 203–19.CrossRefGoogle ScholarPubMed

Yatham, LN, Liddle, PF, Sossi, V, et al. (2012) Positron emission tomography study of the effects of tryptophan depletion on brain serotonin₂ receptors in subjects recently remitted from major depression. Arch Gen Psychiatry 69: 601–9.CrossRefGoogle ScholarPubMed

Aan het Rot, M, Collins, KA, Murrough, JW, et al. (2010) Safety and efficacy of repeated dose intravenous ketamine for treatment resistant depression. Biol Psychiatry 67: 139–45.CrossRefGoogle ScholarPubMed

Abdallah, CG, DeFeyter, HM, Averill, LA, et al. (2018) The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43: 2154–60.CrossRefGoogle ScholarPubMed

Anderson, A, Iosifescu, DV, Macobsen, M, et al. (2019) Efficacy and safety of AXS-05, an oral NMDA receptor antagonist with multimodal activity, in major depressive disorder: results of a phase 2, double blind active controlled trial. Abstract, American Society of Clincal Psychopharmacology Annual Meeting.Google Scholar

Deyama, S, Bang, E, Wohleb, ES, et al. (2019) Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine. Am J Psychiatry 176: 388-400.CrossRefGoogle ScholarPubMed

DiazGranados, N, Ibrahim, LA, Brutsche, NE, et al. (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant depressive disorder. J Clin Psychiatry 71: 1605–11.CrossRefGoogle Scholar

Duman, RS, Voleti, B (2012) Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35: 47–56.CrossRefGoogle ScholarPubMed